Dr. Scott Demarest, MD
Neurology (Epilepsy Physician)
13123 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2009
Licensed in Colorado since 2014, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Epilepsy Physician primary
CO license DR.0053949 (first issued 2014; active) -
Neurology Physician
CO license DR.0053949 (first issued 2014; active) -
Neurology with Special Qualifications in Child Neurology Physician
CO license DR.0053949 (first issued 2014; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 6 payments worth $5,690 in total to this clinician.
| H. Lundbeck A S | $5,100 |
|---|---|
| UCB SA | $360 |
| Lundbeck LLC | $153 |
| Jazz Pharmaceuticals Inc. | $77.16 |
| Honoraria | $5,100 |
|---|---|
| Food and Beverage | $347 |
| Travel and Lodging | $243 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| H. Lundbeck A S Dec 12, 2025 | Honoraria | $3,600 |
| H. Lundbeck A S Nov 18, 2025 | Honoraria | $1,500 |
| UCB SA Jul 14, 2025 | Travel and Lodging Fintepla · Neurology · travel to BOSTON, MA · in-kind | $243 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $76,854 in research payments for these studies, mostly to the institutions running them.
- A phase 2, prospective, interventional, open-label, multi-site, extension study to assess the long-term safety and tolerability of TAK-935 (OV935) as adjunctive therapy in patients with rare epilepsy
Takeda Pharmaceuticals U.S.A., Inc. - A study of soticlestat as an add-on therapy in children and adults with dravet syndrome or lennox-gastaut syndrome
Takeda Pharmaceuticals U.S.A., Inc. - A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03771898
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.